• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , July 14

RANBAXY Laboratories Ltd has received tentative approval from the US Food and Drug Administration (FDA) to manufacture and market zidovudine tablets 300 mg used in combination with other anti-retroviral (ARV) agents in the treatment of HIV infection.

This is the first approval granted by the US regulator for generic zidovudine and Ranbaxy's third tentative approval under the US President's Emergency Plan for AIDS relief.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Dr Reddy's launches Colostrum in tie-up with New Zealand co

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line